Open AccessBlood Component Requirements and Erythrocyte Transfusion and Mortality Related to Hemoglobin Deficit in Phase III Trial of Hemoglobin-Based Oxygen Carrier: HBOC-201
Author(s) -
Jonathan S. Jahr,
John P. Williams
Publication year - 2022
Publication title -
american journal of therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.349
H-Index - 62
eISSN - 1536-3686
pISSN - 1075-2765
DOI - 10.1097/mjt.0000000000001494
Subject(s) - medicine , hemoglobin , blood transfusion , blood component , oxygen , red blood cell transfusion , intensive care medicine , chemistry , organic chemistry
Hemoglobin-based oxygen carriers (HBOCs) may cause coagulopathy, changes in total hemoglobin (THb), and affect mortality. Low total hemoglobin concentrations [THb] during hemorrhage may worsen outcomes.